OBJECTIVE: beta-chemokines were recently demonstrated in active MS-lesions. We tested whether MCP-1 and RANTES can also be detected in CSF and serum of patients with MS and whether release is associated with inflammatory disease activity. MATERIALS AND METHODS: CSF and serum from 34 patients with newly diagnosed relapsing-remitting MS (RR-MS), 17 patients with viral meningitis (VM) and 19 patients with non-inflammatory neurological diseases (NIND) were investigated by ELISA. RR-MS patients underwent lumbar puncture and Gd-enhanced MRI examinations within 2 days. RESULTS: MCP-1 was strong intrathecally released in all patients. Compared to NIND CSF-levels were increased in VM (P<0.001) and were decreased in RR-MS (P<0.05). RANTES was only detected in serum in all patients. Levels were higher in VM and RR-MS compared to NIND (P<0.05). A total of 14/34 RR-MS patients exhibited active Gd-enhancing lesions on MRI. They had lower MCP-1 levels in CSF (P<0.001) and serum (P<0.05) and higher serum levels of RANTES (P<0.05) as compared to patients without active lesions. CONCLUSIONS: MCP-1 and RANTES are differentially released during acute attacks of RR-MS, which might reflect different immunregulatory roles of these beta-chemokines in RR-MS.
OBJECTIVE: beta-chemokines were recently demonstrated in active MS-lesions. We tested whether MCP-1 and RANTES can also be detected in CSF and serum of patients with MS and whether release is associated with inflammatory disease activity. MATERIALS AND METHODS: CSF and serum from 34 patients with newly diagnosed relapsing-remitting MS (RR-MS), 17 patients with viral meningitis (VM) and 19 patients with non-inflammatory neurological diseases (NIND) were investigated by ELISA. RR-MS patients underwent lumbar puncture and Gd-enhanced MRI examinations within 2 days. RESULTS:MCP-1 was strong intrathecally released in all patients. Compared to NIND CSF-levels were increased in VM (P<0.001) and were decreased in RR-MS (P<0.05). RANTES was only detected in serum in all patients. Levels were higher in VM and RR-MS compared to NIND (P<0.05). A total of 14/34 RR-MS patients exhibited active Gd-enhancing lesions on MRI. They had lower MCP-1 levels in CSF (P<0.001) and serum (P<0.05) and higher serum levels of RANTES (P<0.05) as compared to patients without active lesions. CONCLUSIONS:MCP-1 and RANTES are differentially released during acute attacks of RR-MS, which might reflect different immunregulatory roles of these beta-chemokines in RR-MS.
Authors: P Kivisäkk; C Trebst; Z Liu; B H Tucky; T L Sørensen; R A Rudick; M Mack; R M Ransohoff Journal: Clin Exp Immunol Date: 2002-09 Impact factor: 4.330
Authors: Elizabeth R Comini-Frota; Antonio L Teixeira; Janaína P A Angelo; Marcus V Andrade; Doralina G Brum; Damacio R Kaimen-Maciel; Norma T Foss; Eduardo A Donadi Journal: CNS Drugs Date: 2011-11-01 Impact factor: 5.749
Authors: Erzsebet Kovesdi; Alaa Kamnaksh; Daniel Wingo; Farid Ahmed; Neil E Grunberg; Joseph B Long; Christine E Kasper; Denes V Agoston Journal: Front Neurol Date: 2012-07-16 Impact factor: 4.003
Authors: Paul Mh Tran; Sharad Purohit; Eileen Kim; Khaled Bin Satter; Diane Hopkins; Kathleen Waugh; Fran Dong; Suna Onengut-Gumuscu; Stephen S Rich; Marian Rewers; Jin-Xiong She Journal: J Transl Autoimmun Date: 2021-10-16